ENXTPA:IVABiotechs
Assessing Inventiva (ENXTPA:IVA) Valuation After Analyst Support And €172.5m Phase 3 Funding
Recent analyst coverage around Inventiva (ENXTPA:IVA) has picked up following new clinical data on its lead MASH candidate, lanifibranor, and a €172.5 million equity financing to support the ongoing NATiV3 Phase 3 trial.
See our latest analysis for Inventiva.
After jumping on renewed interest around lanifibranor and the recent €172.5 million capital raise, Inventiva’s share price has a 30 day share price return of 26.74% and a year to date share price return of 23.61%. This sits alongside a...